Faron Pharmaceuticals Oy Exercise of options (2600O)
07 October 2021 - 05:00PM
UK Regulatory
TIDMFARN
RNS Number : 2600O
Faron Pharmaceuticals Oy
07 October 2021
Faron Pharmaceuticals Ltd
("Faron or the "Company ")
Exercise of options
Issue of equity
Company announcement, 7 October 2021 at 02:00 AM (EDT) / 07:00
AM (BST) / 09:00 AM (EEST)
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM:
FARN, First North: FARON), a clinical stage biopharmaceutical
company, announces that it has received notifications from option
holders to exercise B options over 2,000 ordinary shares in the
Company at an exercise price of EUR 2.90 (approx. GBP 2.49) and D
options over 9,000 shares in the Company at an exercise price of
EUR 1.09 (approx. GBP 0.93) per share under the Company's 2015
Option Plan ("New Ordinary Shares"). The terms and conditions of
the 2015 Option Plan are available on the Company's website: Option
Plan 2015 .
Applications will be made to the London Stock Exchange and
Nasdaq Helsinki to admit the New Ordinary Shares to trading on AIM
and Nasdaq First North Growth Market, respectively. Admission of
the New Ordinary Shares is expected to occur on or around 15
October 2021 following issue and registration of the New Ordinary
Shares on or around 14 October 2021 ("Registration"). The New
Ordinary Shares will rank pari passu with existing ordinary
shares.
Faron's enlarged issued number of shares immediately following
Registration will be 53,232,032 ordinary shares with voting rights
attached. The Company has no shares in treasury ; therefore upon,
and subject to, Registration, the total number of voting rights in
Faron will be 53,232,032 . This figure may be used by shareholders
as the denominator for the calculations by which they will
determine whether they are required to notify an interest in, or a
change to their interest in, the issued shares and votes of the
Company.
For more information please contact:
Faron Pharmaceuticals Ltd
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
faron@consilium-comms.com
Phone: +44 (0)20 3709 5700
Stern Investor Relations
Julie Seidel
julie.seidel@sternir.com
Phone: +1 (212) 362-1200
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage
biopharmaceutical company developing novel treatments for medical
conditions with significant unmet needs caused by dysfunction of
our immune system. The Company currently has a pipeline based on
the receptors involved in regulation of immune response in
oncology, organ damage and bone marrow regeneration. Bexmarilimab,
a novel anti-Clever-1 humanized antibody, is its investigative
precision immunotherapy with the potential to provide permanent
immune stimulation for difficult-to-treat cancers through targeting
myeloid function. Currently in Phase I/II clinical development as a
potential therapy for patients with untreatable solid tumors,
bexmarilimab has potential as a single-agent therapy or in
combination with other standard treatments including immune
checkpoint molecules. Traumakine is an investigational intravenous
(IV) interferon beta-1a therapy for the treatment of acute
respiratory distress syndrome (ARDS) and other ischemic or
hyperinflammatory conditions. Traumakine is currently being
evaluated in global trials as a potential treatment for
hospitalized patients with COVID-19 and with the 59th Medical Wing
of the US Air Force and the US Department of Defense for the
prevention of multiple organ dysfunction syndrome (MODS) after
ischemia-reperfusion injury caused by a major trauma. Faron is
based in Turku, Finland . Further information is available at
www.faron.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEBUBDGXSGDGBL
(END) Dow Jones Newswires
October 07, 2021 02:00 ET (06:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Mar 2023 to Mar 2024